Eliem cuts in on Tango, proposing acquisition after strategic review
19 Mar 2024
Acquisition
Preview
Source: FierceBiotech
The proposed Tango acquisition could save Eliem from closure, which the biotech has been dancing around since last summer.
Eliem Therapeutics is sashaying away from the brink of closure, joining hands with a private biotech identified as "Tango" after reviewing strategic alternatives.
RA Capital-backed Eliem is set to snap up Tango, another company that has funds affiliated with RA Capital, according to Securities and Exchange Commission documents filed March 18. Currently, there's no webpage for a private biotech called Tango and the company is not listed as part of RA's portfolio.
According to the proposed transaction, Eliem will issue common stock to Tango’s equityholders in exchange for all outstanding equity of Tango, with the company becoming a wholly owned Eliem subsidiary. The proposal means that Tango shareholders would own 15.4% of equity of the company immediately before the deal closes, according to SEC documents.
The proposed exchange ratio values Eliem initially at $110 million right when the deal closes, while Tango valued at $20 million.
If the acquisition goes through, a concurrent private placement of the new company’s common stock would be put into effect. Funds affiliated with RA Capital are expected to purchase a portion of the securities in the concurrent investment, according to SEC filings.
The deal still has to be approved by both companies’ boards and stockholders.
Eliem has been searching for a savior since July 2023, when the biotech shuttered its last pipeline program and launched a search for strategic alternatives. Just a few months before, the nervous system disorder-focused company axed a phase-2-ready depression drug candidate and laid off 55% of staff, citing a “challenging capital environment” as the reason for ending work on its most advanced candidate.
Editor's note: An initial version of this article referred to Tango as "Tango Therapeutics," which is a separate biotech that RA Capital has backed.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.